Mitoxantrone Plus Vinorelbine in Pretreated Patients with Metastatic Breast Cancer

References

• Greenlee RT, Murray T, Bolden S. Cancer statistics. Cancer J Clin 2000; 50: 7–33.
   PubMed Web of Science ®Google Scholar
• Hayes DF, Henderson IC, Shapiro CL. Treatment of metastatic breast cancer: present and future prospects. Semin Oncol 1995; 22 (suppl 5): 5-21.
   Google Scholar
• Norton L. Salvage chemotherapy of breast cancer. Semin Oncol 1994; 21: 19–24.
   PubMed Web of Science ®Google Scholar
• Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163–9.
   PubMedGoogle Scholar
• Silvestris N, D'Aprile M, Andreola G, et al. Rationale for the use of gemcitabine in breast cancer (Review). Int J Oncol 2004; 24: 389–98.
   PubMed Web of Science ®Google Scholar
• Smith IE, Stuart-Harris R, Pavlidis N, et al. Mitoxantrone article (Novantrone) as single agent and in combination chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rev 1983; 10: 37–40.
   PubMed Web of Science ®Google Scholar
• Robertson JF, Williams MR, Todd JH, et al. Mitoxantrone is a useful palliative therapy in advanced breast cancer. Am J Clin Oncol 1989; 12: 393–6.
   PubMed Web of Science ®Google Scholar
• Brufman G, Haim N, Ben-Baruch N, et al. Second-line chemotherapy with mitoxantrone as a single agent in metasta-tic breast cancer. J Chemother 1993; 5: 43–6.
   PubMed Web of Science ®Google Scholar
• Susnjar S, Vasovic S, Neskovic-Kostantinovic Z, et al. Mitoxantrone, 5-fluorouracil and low-dose leucovorin in dox-orubicin-resistant advanced breast cancer patients: a phase II study. Tumori 1999; 85: 478–82.
   PubMed Web of Science ®Google Scholar
• Vogel Cl. Combination of chemotherapy with vinorel-bine and mitoxantrone for metastatic breast cancer: a review. Sem Oncol 1995; 22 (Suppl.) 5: 61-65.
   Google Scholar
• Bruno S, Puerto VL, Mickiewicz E, et al. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol. 1995; 18 (5): 392-6.
   Google Scholar
• Fumoleau P, Delgado T, Delozier A, et al: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11: 1245–52.
   PubMed Web of Science ®Google Scholar
• Romero A, Rabinovich M, Vallejo C, et al: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994; 12: 336–41.
   PubMed Web of Science ®Google Scholar
• Weber BL, Vogel C, Jones S, et al. Intravenous vinorel-bine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol. 1995; 13 (11): 2722–30.
   PubMed Web of Science ®Google Scholar
• Llombart-Cussac A, Pirot X, Rhor-Alvarado A et al: First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II study. Oncology 1998; 55: 384–90.
   PubMed Web of Science ®Google Scholar
• Peacock NW, Burris HA, Dieras V, et al. A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors. Invest New Drugs. 1998; 16 (1): 37–43.
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assos 1958; 53: 457–481.
   Web of Science ®Google Scholar
• Lentner C. Geigy Scientific Tables (‘Exact Confidence Limits for p’); Ciba-Geigy: Switzerland, 1982: 89–102.
   Google Scholar
• Namer M, Soler-Michel P, Turpin F, et al. Results of phase III prospective, randomized trial, comparing mitox-antrone and vinorelbine (MV) in combination with standard FAC/FEC in first-line therapy of metastatic breast cancer. Eur J Cancer 2001; 37 (9): 1132–1140.
   PubMed Web of Science ®Google Scholar
• Berruti A, Sperone P, Boffin' A et al. Phase II study of vinorelbine with protracted fluorouracil infusion as a second or third-line approach for advanced breast cancer patients previ-ously treated with anthracyclines. J Clin Oncol 2000; 18: 3370–3377.
   Google Scholar
• Adams DJ, Knick VC. P - glycoprotein mediated resis-tance to 5-nor-aughydro-vinblastine (Navelbine). Invest NewDrugs 1995; 13: 13–21.
   PubMed Web of Science ®Google Scholar
• Zelek L, Barthier S, Riofrio M et al: Weekly Vinorelbine is an effective palliative regimen offer failure with anthracy-dines and taxanes in metastatic breast carcinoma. Cancer 2001; 92: 2267–2272.
   PubMed Web of Science ®Google Scholar
• Gasparini G, Caffo 0, Barni S et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: A phase II study. J Clin Oncol 1994; 12: 2094-2101.
   Google Scholar
• Terenziani M, Demicheli R, Brambilla C et al. Vinorelbine: An active non-cross resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat 1996; 39: 285–291.
   Web of Science ®Google Scholar
• Terzoli E, Nistico C, Fabi A, et al. Single agent vinorel-bine in pretreated breast cancer patients comparison of two different schedules. J Exp Clin Cancer Res 2004; 23 (2): 207–213.
   PubMed Web of Science ®Google Scholar
• Toi M, Saeki T, Aogi K, et al. Late phase II clinical study of Vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracycline and tax-anes. Jpn J Clin Oncol 2005; 35 (6): 210–315.
   Web of Science ®Google Scholar
• Dinota A, Bilancia D, Romano R, et al. Biweekly administration of gemcitabine and vinorelbine as first-line ther-apy in elderly advanced breast cancer. Breast Cancer Res Treat 2005; 89 (1): 1–3.
   PubMed Web of Science ®Google Scholar
• Konig E, Kurbacher C, Schwonzen M, et al. A phase II study of dose-dense docetaxel and mitoxantrone in the treat-ment of patients with high-risk metastatic breast cancer. Anticancer Drugs 2002; 13 (8): 827–832.
   PubMed Web of Science ®Google Scholar
• Di Constanzo F, Manzione L, Gasperoni S, et al. Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research. Cancer Invest 2004; 22 (3): 331-337. Ejlertsen B, Mouridsen HT, Langkjer ST, et al. Phase III study of intravenous Vinorelbine in combination with epiru-bicin versus epirubicin alone in patients with advanced breast cancer: a Scandinevian Breast Group Trial (50G9403). J Clin Oncol 2004; 22 (12): 2313-2320.
   Google Scholar